Alzheimerundefineds disease (AD), a degenerative disease of the nervous system caused by multiple factors, is a serious threat to human health. The present invention has the advantages of no definite curative effect, large toxic and side effect and the like, and can not effectively prevent the development of AD. Therefore, the development of anti-AD drugs that can change the course of the disease is the focus of the current medical community. Methods A series of biochemical and physical methods were used to study the effects of amyoid (A-type) aggregation and neurotoxicity, and the effects of animal behavior on the transgenic animals were observed by using a series of biochemical and physical methods.
The efficacy and safety of GV-971 in the treatment of mild to moderate Alzheimerundefineds disease (MIQ score 11 ≤ 26) were evaluated. During the clinical study, patients took 450 mg / time oral drugs twice a day. The main end point index of curative effect was the change of cognitive part of Alzheimerundefineds disease rating scale after 36 weeks of treatment. The results showed that GV-971 reached the expectation on the main curative effect index of cognitive function improvement, and had significant statistical and clinical significance. The incidence of adverse events is very similar to that of placebo, especially the toxic and side effects of abnormal amyloidin-related imaging, which is often found in antibody drugs.
The drug is a marine oligosaccharide molecule extracted from the seaweed. Unlike traditional targeting antibody drugs, GV-971 can capture the amyloid protein (A-1) in a multi-position, multi-segment, multi-state, inhibit the formation of A-shaped filaments, and depolymerize the formed filaments into non-toxic monomers. The most recent study found that GV-971 also helps to reduce the progression of Alzheimerundefineds disease by regulating the imbalance of the intestinal flora, remodeling the immune homeostasis of the body, and further reducing the neuroinflammation in the brain.
Investor Contact: :